TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04317937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment
Description: Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record.
Study: NCT01657903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: Toothpaste containing 1450 ppm F - EU level as NaF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate
Description: All study treatments contain 5% w/w KNO3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Description: All study treatments contain 5% w/w KNO3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Description: All study treatments contain 5% w/w KNO3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium nitrate
Description: All study treatments contain 5% w/w KNO3.
Study: NCT01146691

Intervention type: OTHER
Intervention: Alternative Intensivist staffing models
Description: During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.

Intervention type: OTHER
Intervention: Alternative Intensivist staffing models
Description: During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
Study: NCT00837889

Intervention type: DRUG
Intervention: diuretics, inotropica
Study: NCT00039104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03656315

Intervention type: OTHER
Group type: OTHER
Intervention: Airway Assessment
Description: All patients recruited to this study will have an ultrasound of their cricothyroid membrane
Study: NCT04286724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)
Description: Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth
Study: NCT04317937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Treatment
Description: Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record.
Study: NCT03982797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Instillation of IMUNO BCG Moreau RJ
Description: Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
Study: NCT01666821

Intervention type: OTHER
Intervention: Follow-up observation
Description: a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
Study: NCT02815800

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ETHNODYNE VISIO
Study: NCT04251455

Intervention type: PROCEDURE
Intervention: Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue
Description: Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above.
Study: NCT03155022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning and intracoronary ischemic conditioning
Description: RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization.

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning
Description: Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
Study: NCT01314482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200mg bd for 3 days before surgery
Study: NCT01065311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
Study: NCT04468451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 48-hour ROC training program with a standing posture
Description: The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
Study: NCT01065311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Behavioral Analysis System of Psychotherapy
Description: The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatric care
Description: Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard psychiatric care
Description: Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatric care
Description: Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist
Study: NCT05453994

Intervention type: DRUG
Intervention: H. pylori eradication
Description: PPIs-based Antimicrobial agents for H. pylori eradication

Intervention type: DRUG
Intervention: H. pylori eradication
Description: PPIs-based Antimicrobial agents for H. pylori eradication
Study: NCT04713332

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen rich water
Description: Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
Study: NCT04468451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A 24-hour ROC training program with a standing posture
Description: The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A regular therapy program without receiving any ROC training
Description: The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
Study: NCT05712798

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02225743

Intervention type: OTHER
Intervention: Observation Of Temperature
Description: Participants temperature will be recorded perioperatively.
Study: NCT03249311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Study: NCT01879774

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological and motoric tests
Description: 1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological and motoric tests
Description: 1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)
Study: NCT02574130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: 400 mg, nebulizer, every 12 hours, 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 4 ml, nebulizer, every 12 hours, 10 days
Study: NCT03893604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2) 2mA or sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3/FP2) 2mA or sham
Study: NCT00322842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Plus Plerixafor
Description: Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study: NCT01264978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive magnetic stimulation of the quadriceps muscle
Description: During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions.
Study: NCT02068222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/ritonavir (r)
Description: Tablet
Study: NCT01208025

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
Description: 3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
Study: NCT03027180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive airway pressure with different levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive airway pressure with different levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive airway pressure with different levels
Study: NCT01190280

Intervention type: PROCEDURE
Intervention: Cholecystectomy operation
Description: Cholecystectomy after randomization

Intervention type: PROCEDURE
Intervention: Cholecystectomy operation
Description: Cholecystectomy after randomization
Study: NCT02857049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) degustation
Study: NCT01087151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral repeating dose
Study: NCT04713332

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
Study: NCT01932775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTab System
Study: NCT01087151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Intravenous repeating dose
Study: NCT00832052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
Study: NCT04476394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Anaprazole Sodium enteric-coated capsule
Description: \[14C\]-Anaprazole Sodium enteric-coated capsule